Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure

Brian Rini; E. Jason Abel; Laurence Albiges; Axel Bex; James Brugarolas; Ronald M. Bukowski; Jonathan A. Coleman; Charles G. Drake; Robert A. Figlin; Andy Futreal; Hans Hammers; Thomas Powles; W. Kimryn Rathmell; Christopher J. Ricketts; Samra Turajlic; Christopher G. Wood; Bradley C. Leibovich

doi:10.1016/j.clgc.2020.10.005

Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure

Brian Rini, E. Jason Abel, Laurence Albiges, Axel Bex, James Brugarolas, Ronald M. Bukowski, Jonathan A. Coleman, Charles G. Drake, Robert A. Figlin, Andy Futreal, Hans Hammers, Thomas Powles, W. Kimryn Rathmell, Christopher J. Ricketts, Samra Turajlic, Christopher G. Wood, Bradley C. Leibovich

Research output: Contribution to journal › Comment/debate

5 Citations (Scopus)

Abstract

Close to 74,000 cases of renal cell carcinoma (RCC) are diagnosed each year in the United States. The past 2 decades have shown great developments in surgical techniques, targeted therapy and immunotherapy agents, and longer complete response rates. However, without a global cure, there is still room for further advancement in improving patient care in this space. To address some of the gaps restricting this progress, the Kidney Cancer Association brought together a group of 27 specialists across the areas of clinical care, research, industry, and advocacy at the inaugural “Think Tank: Coalition for a Cure” session. Topics addressed included screening, imaging, rarer RCC subtypes, combination drug therapy options, and patient response. This commentary summarizes the discussion of these topics and their respective clinical challenges, along with a proposal of projects for collaboration in overcoming those needs and making a greater impact on care for patients with RCC moving forward.

Original language	English
Pages (from-to)	167-175
Number of pages	9
Journal	Clinical Genitourinary Cancer
Volume	19
Issue number	2
DOIs	https://doi.org/10.1016/j.clgc.2020.10.005
Publication status	Published - 1 Apr 2021

Keywords

Biomarkers
Clinical needs
Registry
Renal cancer
Renal cell carcinoma

Access to Document

10.1016/j.clgc.2020.10.005

Cite this

Rini, B., Abel, E. J., Albiges, L., Bex, A., Brugarolas, J., Bukowski, R. M., Coleman, J. A., Drake, C. G., Figlin, R. A., Futreal, A., Hammers, H., Powles, T., Rathmell, W. K., Ricketts, C. J., Turajlic, S., Wood, C. G., & Leibovich, B. C. (2021). Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure. Clinical Genitourinary Cancer, 19(2), 167-175. https://doi.org/10.1016/j.clgc.2020.10.005

@article{1afc1a1051334059933a90d4e8408445,

title = "Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure",

abstract = "Close to 74,000 cases of renal cell carcinoma (RCC) are diagnosed each year in the United States. The past 2 decades have shown great developments in surgical techniques, targeted therapy and immunotherapy agents, and longer complete response rates. However, without a global cure, there is still room for further advancement in improving patient care in this space. To address some of the gaps restricting this progress, the Kidney Cancer Association brought together a group of 27 specialists across the areas of clinical care, research, industry, and advocacy at the inaugural “Think Tank: Coalition for a Cure” session. Topics addressed included screening, imaging, rarer RCC subtypes, combination drug therapy options, and patient response. This commentary summarizes the discussion of these topics and their respective clinical challenges, along with a proposal of projects for collaboration in overcoming those needs and making a greater impact on care for patients with RCC moving forward.",

keywords = "Biomarkers, Clinical needs, Registry, Renal cancer, Renal cell carcinoma",

author = "Brian Rini and Abel, {E. Jason} and Laurence Albiges and Axel Bex and James Brugarolas and Bukowski, {Ronald M.} and Coleman, {Jonathan A.} and Drake, {Charles G.} and Figlin, {Robert A.} and Andy Futreal and Hans Hammers and Thomas Powles and Rathmell, {W. Kimryn} and Ricketts, {Christopher J.} and Samra Turajlic and Wood, {Christopher G.} and Leibovich, {Bradley C.}",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2021",

month = apr,

day = "1",

doi = "10.1016/j.clgc.2020.10.005",

language = "English",

volume = "19",

pages = "167--175",

journal = "Clinical Genitourinary Cancer",

issn = "1558-7673",

number = "2",

}

Rini, B, Abel, EJ, Albiges, L, Bex, A, Brugarolas, J, Bukowski, RM, Coleman, JA, Drake, CG, Figlin, RA, Futreal, A, Hammers, H, Powles, T, Rathmell, WK, Ricketts, CJ, Turajlic, S, Wood, CG & Leibovich, BC 2021, 'Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure', Clinical Genitourinary Cancer, vol. 19, no. 2, pp. 167-175. https://doi.org/10.1016/j.clgc.2020.10.005

TY - JOUR

T1 - Summary from the Kidney Cancer Association's Inaugural Think Thank

T2 - Coalition for a Cure

AU - Rini, Brian

AU - Abel, E. Jason

AU - Albiges, Laurence

AU - Bex, Axel

AU - Brugarolas, James

AU - Bukowski, Ronald M.

AU - Coleman, Jonathan A.

AU - Drake, Charles G.

AU - Figlin, Robert A.

AU - Futreal, Andy

AU - Hammers, Hans

AU - Powles, Thomas

AU - Rathmell, W. Kimryn

AU - Ricketts, Christopher J.

AU - Turajlic, Samra

AU - Wood, Christopher G.

AU - Leibovich, Bradley C.

PY - 2021/4/1

Y1 - 2021/4/1

N2 - Close to 74,000 cases of renal cell carcinoma (RCC) are diagnosed each year in the United States. The past 2 decades have shown great developments in surgical techniques, targeted therapy and immunotherapy agents, and longer complete response rates. However, without a global cure, there is still room for further advancement in improving patient care in this space. To address some of the gaps restricting this progress, the Kidney Cancer Association brought together a group of 27 specialists across the areas of clinical care, research, industry, and advocacy at the inaugural “Think Tank: Coalition for a Cure” session. Topics addressed included screening, imaging, rarer RCC subtypes, combination drug therapy options, and patient response. This commentary summarizes the discussion of these topics and their respective clinical challenges, along with a proposal of projects for collaboration in overcoming those needs and making a greater impact on care for patients with RCC moving forward.

AB - Close to 74,000 cases of renal cell carcinoma (RCC) are diagnosed each year in the United States. The past 2 decades have shown great developments in surgical techniques, targeted therapy and immunotherapy agents, and longer complete response rates. However, without a global cure, there is still room for further advancement in improving patient care in this space. To address some of the gaps restricting this progress, the Kidney Cancer Association brought together a group of 27 specialists across the areas of clinical care, research, industry, and advocacy at the inaugural “Think Tank: Coalition for a Cure” session. Topics addressed included screening, imaging, rarer RCC subtypes, combination drug therapy options, and patient response. This commentary summarizes the discussion of these topics and their respective clinical challenges, along with a proposal of projects for collaboration in overcoming those needs and making a greater impact on care for patients with RCC moving forward.

KW - Biomarkers

KW - Clinical needs

KW - Registry

KW - Renal cancer

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85099505539&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2020.10.005

DO - 10.1016/j.clgc.2020.10.005

M3 - Comment/debate

C2 - 33358149

AN - SCOPUS:85099505539

SN - 1558-7673

VL - 19

SP - 167

EP - 175

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

IS - 2

ER -

Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure

Abstract

Keywords

Access to Document

Other files and links

Cite this